Inebilizumab binds CD19 on B-lineage cells and, via its afucosylated IgG1 Fc, recruits effector mechanisms to kill the bound cell—NK cell ADCC, macrophage phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC)—depleting CD19+ cells.